Remodulin and Pulseless electrical activity - a phase IV clinical study of FDA data

Summary:

Pulseless electrical activity is reported as a side effect among people who take Remodulin (treprostinil sodium), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Opsumit, and have Pulmonary hypertension.

The phase IV clinical study analyzes which people have Pulseless electrical activity when taking Remodulin. It is created by eHealthMe based on reports of 55,815 people who have side effects when taking Remodulin from the FDA, and is updated regularly.

What is Remodulin?

Remodulin has active ingredients of treprostinil sodium. It is often used in primary pulmonary hypertension. eHealthMe is studying from 55,843 Remodulin users. Check the latest studies of Remodulin.

What is Pulseless electrical activity?

Pulseless electrical activity is found to be associated with 400 drugs and 525 conditions by eHealthMe. Check the latest studies of Pulseless electrical activity.

On Jul, 05, 2026

55,815 people reported to have side effects when taking Remodulin.
Among them, 33 people (0.06%) have Pulseless electrical activity.

Could Remodulin cause Pulseless electrical activity?

Among these 33 people:

How long have people been on Remodulin when they have Pulseless electrical activity? *

What is the gender of people who have Pulseless electrical activity when taking Remodulin? *

female: 53.33 %
male: 46.67 %

What is the age of people who have Pulseless electrical activity when taking Remodulin? *

What are other drugs people take besides Remodulin? *

What are other side effects people have besides Pulseless electrical activity? *

Cardiac Arrest: 7 people, 21.21%
Dyspnea (difficult or laboured breathing): 6 people, 18.18%
Coughing Up Blood: 6 people, 18.18%
Hypotension (abnormally low blood pressure): 6 people, 18.18%
Right Ventricular Failure (right half of the heart fails to work): 6 people, 18.18%
Fever: 5 people, 15.15%
Head Injury: 5 people, 15.15%
Oxygen Saturation Decreased: 5 people, 15.15%
Concomitant Disease Aggravated (advanced due to some of accompanying): 4 people, 12.12%
Cardiac Failure Chronic: 4 people, 12.12%

What are the existing conditions these people have? *

Pulmonary Hypertension (increase in blood pressure in the lung artery): 8 people, 24.24%
Systemic Sclerosis (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 1 person, 3.03%
Sarcoidosis (an inflammatory disease that affects multiple organs in the body, but mostly the lungs and lymph glands): 1 person, 3.03%
Pulmonary Veno-Occlusive Disease (obstructive disease of the pulmonary veins): 1 person, 3.03%
Lipids Increased (excess lipid in body): 1 person, 3.03%
Insomnia (sleeplessness): 1 person, 3.03%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Remodulin and have Pulseless electrical activity?

- Check whether Pulseless electrical activity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Remodulin:

Remodulin (55,843 reports)

Browse all side effects of Remodulin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulseless electrical activity:

Pulseless electrical activity (400 drugs)

Browse all the conditions that are associated with Pulseless electrical activity:

Pulseless electrical activity (525 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on treprostinil sodium (the active ingredients of Remodulin) and Remodulin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.